The stock price of Dynavax Technologies Corp. (NASDAQ: DVAX) has plunged by -1.71 when compared to previous closing price of 11.69, but the company has seen a -4.41% decline in its stock price over the last five trading sessions. Seeking Alpha reported 2024-03-24 that Dynavax’s core asset, HEPISLAV-B, saw a 69% increase in sales in FY23, making the company cash flow positive. The company’s CpG 1018 vaccine candidates are advancing in mid-stage trials, with Heplisav potential sales reaching $400 million by FY27. Dynavax’s stock has been trading at the lower end of its range, but with positive prospects and a strong balance sheet, it presents a solid long-term investment opportunity.
Is It Worth Investing in Dynavax Technologies Corp. (NASDAQ: DVAX) Right Now?
Company’s 36-month beta value is 1.29.Analysts have differing opinions on the stock, with 5 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for DVAX is 130.22M, and currently, short sellers hold a 13.80% ratio of that floaft. The average trading volume of DVAX on April 17, 2024 was 1.91M shares.
DVAX’s Market Performance
The stock of Dynavax Technologies Corp. (DVAX) has seen a -4.41% decrease in the past week, with a -4.65% drop in the past month, and a -18.97% fall in the past quarter. The volatility ratio for the week is 2.01%, and the volatility levels for the past 30 days are at 2.23% for DVAX. The simple moving average for the past 20 days is -5.33% for DVAX’s stock, with a -15.38% simple moving average for the past 200 days.
Analysts’ Opinion of DVAX
Many brokerage firms have already submitted their reports for DVAX stocks, with Goldman repeating the rating for DVAX by listing it as a “Neutral.” The predicted price for DVAX in the upcoming period, according to Goldman is $20 based on the research report published on February 01, 2024 of the current year 2024.
JMP Securities, on the other hand, stated in their research note that they expect to see DVAX reach a price target of $22. The rating they have provided for DVAX stocks is “Mkt Outperform” according to the report published on September 27th, 2022.
Goldman gave a rating of “Buy” to DVAX, setting the target price at $38 in the report published on January 06th of the previous year.
DVAX Trading at -7.74% from the 50-Day Moving Average
After a stumble in the market that brought DVAX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -24.16% of loss for the given period.
Volatility was left at 2.23%, however, over the last 30 days, the volatility rate increased by 2.01%, as shares sank -1.79% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -9.88% lower at present.
During the last 5 trading sessions, DVAX fell by -4.41%, which changed the moving average for the period of 200-days by -12.22% in comparison to the 20-day moving average, which settled at $12.13. In addition, Dynavax Technologies Corp. saw -17.81% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at DVAX starting from Burgess Justin, who sale 20,526 shares at the price of $12.78 back on Mar 01 ’24. After this action, Burgess Justin now owns 0 shares of Dynavax Technologies Corp., valued at $262,322 using the latest closing price.
Janssen Robert, the SVP and CMO of Dynavax Technologies Corp., sale 1,500 shares at $15.00 during a trade that took place back on Jan 04 ’24, which means that Janssen Robert is holding 49,925 shares at $22,500 based on the most recent closing price.
Stock Fundamentals for DVAX
Current profitability levels for the company are sitting at:
- -0.11 for the present operating margin
- 0.78 for the gross margin
The net margin for Dynavax Technologies Corp. stands at -0.03. The total capital return value is set at -0.03. Equity return is now at value -1.06, with -0.64 for asset returns.
Based on Dynavax Technologies Corp. (DVAX), the company’s capital structure generated 0.29 points at debt to capital in total, while cash flow to debt ratio is standing at 0.39. The debt to equity ratio resting at 0.41. The interest coverage ratio of the stock is -3.38.
Currently, EBITDA for the company is 20.98 million with net debt to EBITDA at 5.92. When we switch over and look at the enterprise to sales, we see a ratio of 6.92. The receivables turnover for the company is 5.22for trailing twelve months and the total asset turnover is 0.23. The liquidity ratio also appears to be rather interesting for investors as it stands at 13.81.
Conclusion
In a nutshell, Dynavax Technologies Corp. (DVAX) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
